Venock Reports Safety/Efficacy of Its Automated Closure Device for Large Bore Venous Access Sites as Alternative to Standard Manual Compression of Veins/Arteries in Interventional Procedures

Vernock announced today it has successfully completed the demonstration of safety and efficacy of its large bore closure system in animal studies.

Venock is developing a vascular closure system for large bore punctures (up to 30 Fr and larger) in vessels following transvenous catheter-based therapies such as atrial ablations, leadless pacemaker implantations, ECMO, and various structural heart therapies such as Mitral- and Tricuspid- Valve Repair and Replacement.

The Venock device (see animation) was successfully used in multiple acute porcine studies to percutaneously close large bore access sites in the jugular vein. These access sites, whose diameter were as large as the vein itself, were immediately closed in a blood-tight manner without disrupting the venous blood flow or causing a stenosis.

“The Venock device is designed to attain large-bore venous closure in under a minute, thus saving time and money, while significantly reducing patient discomfort and time to discharge when compared to the recovery time from manual compression,” said Prof. Dr. Horst Sievert, CardioVascular Center, Frankfurt.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.